| Gene symbol | PMEL | Synonyms | D12S53E, HMB-45, HMB45, ME20, ME20-M, ME20M, P1, P100, PMEL17, SI, SIL, SILV, gp100 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | premelanosome protein | ||||
| GTO ID | GTC0052 |
| Trial ID | NCT00610311 |
| Disease | Skin Cancer | Metastatic Melanoma |
| Altered gene | gp100 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | gp100:154-162 TCR-T cells |
| Co-treatment | ALVAC gp100 Vaccine |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization |
| Year | 2008 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 080055|08-C-0055 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||||||
|
|||||||||||||||||